Alembic Ltd (ALEMBICLTD)

₹99.2▲0.15%

Get free price alerts. Set up your Free investment account to get Live Prices. >

Overview

Fundamentals

Q3 '23 Results

Technicals

News and Events

Alembic Ltd share Performance

₹98.3
₹102.4
₹99.2
0.91%
Low
Day's Volatility:4.13%
High
3.23%
₹66.3
₹107.65
₹99.2
33.17%
Low
52 Weeks Volatility:41.68%
High
8.52%

Returns %
1 Month Return	+ 5.88 %
3 Month Return	-2.84 %
1 Year Return	+ 40.7 %

Market Stats
Previous Close	₹₹99.05
Open	₹₹99.60
Volume	₹27.45L
Upper Circuit	₹-
Lower Circuit	₹-
Market Cap	₹₹2,543.42Cr

Company Information

Alembic Ltd is one of India's most experienced manufactures of bulk drugs, pharmaceuticals, and formulations in human and animal healthcare. With a 100-year legacy of operations, they are committed to continually improving the quality of life and healthcare in over 75 countries worldwide. The ISO9002 and ISO14001 certified company manufacturing practices and facilities follow WHOGMP guidelines. Their product range include medicines, chemicals, bulk drugs such as penicillin, other antibiotics, and formulations. With factories in Vadodara, Gujarat, and Solan, Himachal Pradesh, the company has seen tremendous success over the years. From establishing a penicillin plant in 1961, launching of the top selling Erythromycin brand Althrocin in 1972 to manufacturing Cephalosporin C in 2001, Zero - a new generation no calories Sucralose Based Sugar Substitute in 2005, and setting up a formulation manufacturing facility in Baddi with a capacity of 900 million tablets and 600 liquid oral bottles in 2017, Alembic Ltd and its offerings have grown exponentially. Last year, the company acquired the Non-Oncology Business of Dabur Pharma Ltd and entered into a licensing agreement with UCB Belgium while adding new API facilities.

Share Price: ₹99.20 per share as on 16 May, 2024 04:01 PM
Market Capitalisation: ₹2,543.42Cr as of today
Revenue: ₹49.04Cr as on March 2024 (Q1 24)
Net Profit: ₹21.29Cr as on March 2024 (Q1 24)
Listing date: 04 Jan, 1995
Chairperson Name: Chirayu R Amin

Organisation	Alembic Ltd
Headquarters	Vadodara
Industry	Realty
E-voting on shares	Click here to vote

Key events for Alembic Ltd

Alembic Ltd Stock Gains on Q4 Results Announcement - 15 May, 2024
Alembic Ltd's stock gained 14.49% on high-frequency trading after the announcement of its Q4FY24 results. Alembic Pharma's revenue missed estimates but EBITDA beat expectations due to cost optimization measures. Analysts retain a HOLD rating with a decreased target price.
Alembic Reports Strong Q4 Results; Motilal Oswal Raises Earnings Estimates - 14 May, 2024
Alembic Ltd's Q4FY24 net profit soared by 425% YoY to Rs 21 crore, while its total income rose by 30.7% YoY to Rs 51 crore. Additionally, Motilal Oswal raised the company's earnings estimates for FY25/FY26 and valued the stock on an SoTP-basis with a target price of INR 960, reiterating a neutral rating.
Alembic Plans to Launch 25 Products in US Generic Portfolio - 13 May, 2024
Alembic Ltd reported a decent set of Q4 numbers and announced plans to ramp up their US generic portfolio with 25 product launches this year. The company does not plan any major capex, which should lead to improved margins.
Alembic Pharmaceuticals FY24 EPS Beats Expectations, Revenues Lag - 11 May, 2024
Alembic Pharmaceuticals reported an 11% YoY increase in revenue to ₹62.6b and a net income of ₹6.16b, up 80% from FY23. The profit margin increased to 9.8%, driven by higher revenue. However, the revenue missed analyst estimates by 1.2%. Looking ahead, Alembic forecasts an average annual growth rate of 11% for the next three years compared to 10% for the Indian pharmaceutical industry. The company's shares are down 4.8% from a week ago.
Alembic Pharmaceuticals Posts Strong FY24 Results - 10 May, 2024
Alembic Pharmaceuticals reports an 80% YoY growth in net profit to Rs 616 crore, with net sales rising 10% to Rs 6,229 crore and EBITDA surging 41% to Rs 961 crore. The India-branded business achieved 3% growth generating a topline of Rs 503 crore.
Alembic Pharma Reports Strong Q4 Results and FDA Approvals - 09 May, 2024
Alembic Pharmaceuticals reports strong growth in Q4 FY24 with a YoY increase in net sales by 8% and net profit by 17%. The company also received multiple USFDA product approvals during the period April 1 to May 8. Alembic's India branded business achieved a 3% growth while the US Generics segment experienced a 19% growth YoY.
Alembic Pharmaceuticals Receives Establishment Inspection Report from US FDA - 07 May, 2024
Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its Oncology Formulation Facility, completing EIRs for all of its USFDA facilities.
Alembic Pharmaceuticals Receives Establishment Inspection Report from USFDA - 06 May, 2024
The United States Food and Drug Administration has issued an establishment inspection report to Alembic Pharmaceuticals for its oncology facility in Gujarat. The EIR confirms that the company's formulation facility meets the regulatory standards of the US drug regulator. Alembic Pharmaceuticals has also announced that all of its USFDA facilities have received EIRs.
Alembic Pharmaceuticals CEO Has Net Worth of Rs 15850 Crore - 03 May, 2024
Chirayu Amin, the chairman and CEO of Alembic Pharmaceuticals Ltd., has a real-time net worth of Rs 15850 crore as of May 3. The company gets more than a third of its annual revenue from the domestic market selling generic drugs.

Fundamentals of Alembic Ltd

Insights on Alembic Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 0.89% to 1.07% in Mar 2024 quarter
POSITIVE IMPACT
Price Rise
In the last 7 days, ALEMBICLTD stock has moved up by 14.7%
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 41.55 Cr → 51.08 Cr (in ₹), with an average increase of 18.7% per quarter
POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 61.4 Cr → 72.15 Cr (in ₹), with an average increase of 14.9% per quarter
NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 70.88% of holdings in Mar 2024 quarter
NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 122.3% return, outperforming this stock by 140.9%
NO EFFECT
Against Peers
In the last 1 year, Zydus Lifesciences Ltd has given 93.2% return, outperforming this stock by 52.5%
NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 28.17% to 28.00% in Mar 2024 quarter